 |
|
|
|
|
|
|
|
|
|
 |
|
| |
|
Serenex, Inc. -- (ACQUIRED)
HEALTHvision Inc. -- (ACQUIRED)
Hansen Medical, Inc. -- (IPO, NASDAQ:HNSN)
MetaWorks, Inc. -- (ACQUIRED)
ViaCell, Inc. -- (IPO, NASDAQ:VIAC / ACQUIRED)
eMed Technologies (ACQUIRED)
endoVia Medical, Inc. (ACQUIRED)
Synthon Chiragenics Corp. (ACQUIRED)
U.S. CareLink, Inc. (ACQUIRED)
GelTex Pharmaceuticals Inc. -- (IPO, NASDAQ:GLTX / ACQUIRED)
EPIX Medical, Inc. -- (IPO, NASDAQ:EPIX)
Alpha-Beta Technologies, Inc. -- (IPO, NASDAQ:ABTI)
|
|
| |
|
 |
BioValve Technologies, Inc. -- speciality drug delivery company
BioValve Technologies, Inc. is a specialty drug delivery company focusing on the development of the optimized delivery of new chemical entities that support the treatment of conditions of the central nervous system. The lead agents in BioValve's portfolio are D1 and D2 selective dopamine agonists for treatment of Parkinson's disease and schizophrenia. BioValve currently has multiple pharmaceutical collaborations in place and is developing several product-device combinations through FDA approval. BioValve is also the parent company of Valeritas, LLC, which was spun out of BioValve to develop the V-goTM, a novel disposable basal-bolus insulin patch for type 2 Diabetics.
www.biovalve.com
|
| |
| ^ back to top |
| |
| |
| Coserics, LLC |
Coserics, LLC -- supportive-care oncology pharmaceuticals
Coserics is a Durham, North Carolina-based biotech company developing treatments for the supportive-care oncology market. The company's lead compound, SNX-1012, is in phase 2 clinical testing for treatment of chemotherapy induced oral mucositis in solid tumor patients.
|
| |
| ^ back to top |
| |
| |
 |
Sopherion Therapeutics, Inc. -- oncology-focused specialty biopharmaceuticals
Sopherion Therapeutics is a biopharmaceutical company focused on developing and marketing anti-cancer therapies for patients suffering with advanced cancer, including metastatic disease. Sopherion's lead product is Myocet®, a liposome-encapsulated doxorubicin-citrate complex. Extensive clinical studies of Myocet® in women with breast cancer have shown that the severe toxicity of doxorubicin to the heart and the cells that line the gastrointestinal tract can be significantly moderated while the efficacy of the drug is maintained. Myocet® has been approved by the European and Canadian regulatory agencies for first line therapy for patients with metastatic breast cancer. Sopherion is currently conducting a pivotal Phase 3 registration study of Myocet® for the first line treatment for patients with metastatic HER2+ breast cancer in combination with Genentech's Herceptin (trastuzumab). Results from the Phase 3 study are expected in 2009.
www.sopherion.com
|
| |
| ^ back to top |
| |
| |
 |
Targanta Therapeutics, Corp. (NASDAQ:TARG) -- developing novel antibioticsbacterials for serious infections
Targanta Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company Targanta is developing its lead antibiotic, oritavancin, in an intravenous (IV) formulation for the treatment of serious gram-positive bacterial infections, including complicated skin and skin structure infections, or cSSSI, and bacteremia, a blood stream infection. Targanta submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in February 2008 seeking to commercialize IV oritavancin for the treatment of cSSSI. Additionally, Targanta is developing a number of antibacterial agents currently in pre-clinical development including an oral version of oritavancin targeting Clostridium difficile-related conditions. Targanta has exclusive worldwide rights to 's strategy is to develop oritavancin into a leading therapy worldwide for the treatment of serious gram-positive infections, initially for the treatment of cSSSI and subsequently for other indications. The Company has operations in Cambridge, MA, Indianapolis, IN, and Montreal, Québec, Canada. Seaflower was the lead investor in Targanta's first two venture financing rounds, negotiated the acquisition of oritavancin, and recruited the management team.
Targanta raised $57.5 million in an IPO on NASDAQ in October 2007. The Company's common stock trades on the NASDAQ under the symbol: TARG
www.targanta.com
|
| |
| ^ back to top |
| |
| |
 |
Valeritas, Inc. -- novel, convenient insulin delivery solutions for diabetic patients
Valeritas, Inc. is a medical technologies company serving the fast-growing diabetes market with proprietary drug delivery systems. The company's lead product, V-Go™, is an FDA-approved, simple-to-use, disposable insulin delivery device that provides both continuous basal dosing and on-demand mealtime bolus dosing. The V-Go™ is designed to help enhance glycemic control and to improve compliance in type II diabetics.
www.valeritas.com
|
| |
| ^ back to top |
| |
| |
 |
Zelos Therapeutics, Inc. -- PTH therapies for osteoporosis and other diseases
Zelos Therapeutics specializes in the development of innovative treatments for bone disorders and related indications in large, underserved markets. Zelos is advancing a portfolio of product opportunities into late stage clinical trials and pursuing programs linked by the common mechanism of stimulating bone formation to provide therapeutic benefit in the following key indications: osteoporosis; bone marrow/stem cell transplantation; fracture repair; renal bone disease; and multiple myeloma. Zelos's lead compound is ZT-031, a proprietary cyclic 31-amino acid parathyroid hormone (PTH) analog. In a twelve- month Phase 2 study in postmenopausal women with low bone mass, ZT-031 demonstrated its capacity as a powerful bone formation agent, having a rapid onset of effect leading to clinically important increases in bone mineral density (BMD) with low potential for calcium related toxicity. Our target markets include the large market in osteoporosis created by Lilly's Forteo® (teriparatide). Zelos Therapeutics is headquartered in West Conshohocken, Pennsylvania. Seaflower was the lead investor in Zelos's Series A venture capital financing round, incubated the company's initial U.S. headquarters, and recruited the initial management team.
www.zelostherapeutics.com
|
| |
| ^ back to top |
| |
| |
| |
|
 |
Serenex, Inc. -- proteomics-based drug discovery and development
Serenex is an integrated drug discovery and development company with a novel proteomics discovery platform. Serenex is a leader in the discovery and development of small molecule Hsp90 inhibitors. Hsp90 is an important chaperone protein that regulates the folding and degradation of client proteins that play key roles in oncology, inflammatory diseases, fungal infection resistance, viruses and neurodegenerative diseases such as Alzheimer's. Serenex has ongoing programs in all of these areas. The company's most advanced clinical program, SNX-5422, is a novel, orally bioavailable, small molecule inhibitor of Heat Shock Protein 90 (Hsp90). SNX-5542 is currently in Phase 1 oncology trials for solid tumors and hematological cancers.
Serenex was acquired in April 2007 by Pfizer. Acquisition terms were not publicly disclosed.
|
| |
| ^ back to top |
| |
| |
 |
HEALTHvision Inc. -- a leading Internet-based healthcare solutions provider
HEALTHvision is an Internet-based healthcare solutions company addressing the needs of large integrated healthcare delivery networks. The company's Web-based infrastructure, e-healthSOURCE, is the most widely used in the industry, hosting more than 7.5 million unique patient records. More than 350 healthcare organizations use the company's solutions to make health care easier for their key audiences - a number that represents more than 23,000 clinicians (including 11,000 physicians), thousands of patients and millions of consumers. HEALTHvision was acquired in October 2007 for approximately $47 million.
|
| |
| ^ back to top |
| |
| |
 |
Hansen Medical, Inc. (IPO)
Hansen Medical, Inc., develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. Its first product, the Sensei Robotic Catheter system, is a robotic navigation system that enables clinicians to place mapping catheters in hard-to-reach anatomical locations within the heart easily, accurately and with stability during complex cardiac arrhythmia procedures. The Sensei system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data and has been cleared by the U.S. Food & Administration (FDA) for manipulation and control of certain mapping catheters in Electrophysiology (EP) procedures. In the European Union, the Sensei system is cleared for use during EP procedures, such as guiding catheters in the treatment of atrial fibrillation (AF).
Hansen Medical raised $90 million in an IPO on NASDAQ in November 2006.
|
| |
| ^ back to top |
| |
| |
 |
MetaWorks, Inc. -- evidence-based medical information services
MetaWorks is a leading provider of systematic reviews, meta-analyses and other evidence-based-information services for more than 50 companies in the pharmaceutical, biotechnology, medical device, hospital, and health care provider industries. MetaWorks Inc. gained a reputation as one of the healthcare industry's most expert and reliable sources for Evidence-Based Medical Information and technology. Seaflower was the lead investor in MetaWorks' first venture capital financing round. MetaWorks was acquired in January 2006 by United BioSource Corp.
|
| |
| ^ back to top |
| |
| |
 |
ViaCell, Inc. (IPO, NASDAQ:VIAC)
ViaCell Inc. is a clinical-stage biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company is developing a pipeline of proprietary product candidates intended to address cancer, infertility, and cardiac diseases. ViaCell's proprietary technologies include Selective Amplification technology, which the Company believes will enable the development of high- definition stem cell products based on the isolation, purification and significant expansion of targeted stem cell populations. ViaCell is using these assets to develop a cord blood-derived stem cell therapeutic, CB001, the Company's lead stem cell therapy product candidate, which is currently in a Phase I clinical trial. ViaCell also markets its Viacord umbilical cord blood preservation product, which is used primarily for pediatric bone marrow transplants. Seaflower was the lead investor in ViaCell's first two venture capital financing rounds. Jim Sherblom served as Acting CEO for 10 months.
ViaCell completed an IPO on NASDAQ in January 2005, and was subsequently acquired by PerkinElmer in October 2007 for $300 million. |
| |
| ^ back to top |
| |
| |
 |
eMed Technologies (ACQUIRED)
eMed is a provider of Picture Archiving and Communications Systems (PACS) and web-based medical imaging radiology solutions. eMed's product suite includes PACS components to capture, compress, distribute, display and store medical images, RIS and RIS integration, and web-enabled image and report distribution for clinicians. Today, more than 7,800 radiologists and 2,000 hospitals and imaging centers use eMed image management, teleradiology and web solutions to manage images and grow their business. Seaflower was the lead investor in eMed's initial venture capital financing round.
eMed Technologies was acquired for $47 million in October 2004 by Cedara Software Corp.
|
| |
| ^ back to top |
| |
| |
 |
endoVia Medical, Inc. (ACQUIRED)
endoVia Medical is a medical technology company developing second generation computer-assisted surgical devices for minimally invasive surgery (MIS) and interventional medicine. endoVia has developed a robotic guidance system for controlling laparoscopic and catheter-based instruments that will open large, new patient populations to less invasive procedures. endoVia is developing two proprietary product platforms: the Laprotek™ System for MIS; and the catheter-based Endoluminal Surgery System for interventional medicine. Seaflower was the lead investor in endoVia's initial venture capital financing round.
endoVia was acquired in 2005 by Hansen Medical. |
| |
| ^ back to top |
| |
| |
 |
Synthon Chiragenics Corp. (ACQUIRED)
Synthon is the world-leader in carbohydrate-based chiral technology for pharmaceuticals. The company uses its proprietary technology to economically construct the most challenging chiral molecules, which serve as cores for drugs being developed in the fastest-growing therapeutic areas. Seaflower co-founded Synthon and was the lead investor in Synthon's initial two financing rounds.
Synthon was acquired by Avecia in 2003.
|
| |
| ^ back to top |
| |
| |
U.S. CareLink, Inc. (ACQUIRED)
U.S. CareLink is an Internet-based clinical information company founded to develop a Web-based ambulatory care management system that allows physicians, patients and family members to share information online through easy-to-use Web technology. Seaflower was the lead investor in U.S. CareLink's first venture capital financing round.
U.S. CareLink was acquired in 1999 by HEALTHvision. |
| |
| ^ back to top |
| |
| |
 |
GelTex Pharmaceuticals Inc. (IPO, NASDAQ:GLTX / ACQUIRED)
GelTex was founded to develop and commercialize a new class of non-absorbable pharmaceuticals for the selective elimination of substances resulting from certain disease states or whose elimination will have a beneficial medical effect. The company's lead product, Renagel® brand sevelamer hydrochloride, was granted marketing approval by the FDA in 1998 for the reduction of serum phosphorus in hemodialysis patients. GelTex's second product, Welchol brand colesevelam hydrochloride, was granted marketing approval by the FDA in 2000 for the treatment of hypercholesterolemia, a condition characterized by undesirably high cholesterol levels. The company is also developing treatments for non-systemic infections, oral mucositis, cancer, and iron overload. Jim Sherblom was an investor in GelTex's initial round of seed funding.
GelTex completed an IPO in November 1995, and was subsequently acquired by Genzyme Corp. in 2000 for $1 billion. |
| |
| ^ back to top |
| |
| |
 |
EPIX Medical, Inc. (IPO, NASDAQ:EPIX)
EPIX Medical is a specialty pharmaceutical company founded to develop targeted contrast agents to transform the diagnosis and clinical management of cardiovascular disease and to improve the capability of magnetic resonance imaging (MRI) as a diagnostic tool for a variety of diseases. The Company's principal product under development, MS-325, is an injectable intravascular MRI contrast agent designed for multiple vascular imaging applications, including peripheral vascular disease and coronary artery disease. Jim Sherblom was an investor in one of EPIX Medical's early financing rounds.
EPIX completed an IPO in March 1995. |
| |
| ^ back to top |
| |
| |
 |
Alpha-Beta Technologies, Inc. (IPO, NASDAQ:ABTI)
Alpha-Beta was founded to research and develop new classes of carbohydrate and antifungal products. The company's lead product was Betafectin for inflammatory bowel disease (IBD) and the prevention of serious post-operative infections in non-colorectal gastrointestinal surgery patients. Jim Sherblom was an investor in Alpha-Beta's initial seed round of funding.
Alpha-Beta completed an IPO in 1992.
|
| |
| ^ back to top |
| |
| |
|
|
 |
|
|
|
|
|
|
|
 |
|
|
|
